Lupin launches plaque psoriasis treatment spray in US market

New Delhi: Drug major Lupin announced the launch of Desoximetasone Topical Spray, used for the treatment of plaque psoriasis, in the US market.

"Lupin's Desoximetasone Topical Spray, 0.25 percent, is the generic equivalent of Taro Pharmaceuticals U.S.A Inc.'s Topicort Topical Spray, 0.25 percent.

It is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older," the company said in a regulatory filing.

Quoting IQVIA MAT May 2018 data, Lupin said Desoximetasone Topical Spray, 0.25 percent, had annual sales of approximately USD 18.7 million in the US.